D. Mark Layton

3.2k total citations
62 papers, 1.5k citations indexed

About

D. Mark Layton is a scholar working on Physiology, Pediatrics, Perinatology and Child Health and Hematology. According to data from OpenAlex, D. Mark Layton has authored 62 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Physiology, 20 papers in Pediatrics, Perinatology and Child Health and 20 papers in Hematology. Recurrent topics in D. Mark Layton's work include Erythrocyte Function and Pathophysiology (20 papers), Neonatal Health and Biochemistry (18 papers) and Hemoglobinopathies and Related Disorders (16 papers). D. Mark Layton is often cited by papers focused on Erythrocyte Function and Pathophysiology (20 papers), Neonatal Health and Biochemistry (18 papers) and Hemoglobinopathies and Related Disorders (16 papers). D. Mark Layton collaborates with scholars based in United Kingdom, United States and Italy. D. Mark Layton's co-authors include M. R. A. LALLOZ, G J Mufti, A. J. Bellingham, Roopen Arya, Antonio Pagliuca, Irene Roberts, Anastasios Karadimitris, K. H. Nicolaides, António Almeida and Alastair Baker and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Genetics.

In The Last Decade

D. Mark Layton

62 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Mark Layton United Kingdom 19 653 387 378 368 275 62 1.5k
Arnulf Pekrun Germany 25 771 1.2× 600 1.6× 812 2.1× 620 1.7× 247 0.9× 70 2.2k
Jean‐Antoine Ribeil France 26 871 1.3× 307 0.8× 701 1.9× 976 2.7× 277 1.0× 79 2.0k
Luciano Baronciani Italy 22 1.1k 1.7× 428 1.1× 194 0.5× 227 0.6× 175 0.6× 84 1.8k
MH Freedman Canada 27 846 1.3× 174 0.4× 582 1.5× 384 1.0× 440 1.6× 64 1.9k
Masue Imaizumi Japan 25 818 1.3× 113 0.3× 886 2.3× 205 0.6× 423 1.5× 101 2.0k
Corinne Pondarré France 23 788 1.2× 138 0.4× 709 1.9× 725 2.0× 104 0.4× 80 1.9k
Alessandra Meloni Italy 22 282 0.4× 94 0.2× 452 1.2× 328 0.9× 161 0.6× 81 1.7k
Fiorina Giona Italy 23 590 0.9× 354 0.9× 331 0.9× 374 1.0× 80 0.3× 88 1.3k
Tohru Ikuta United States 20 542 0.8× 274 0.7× 680 1.8× 789 2.1× 104 0.4× 48 1.6k
William Krivit United States 21 537 0.8× 488 1.3× 318 0.8× 241 0.7× 224 0.8× 58 1.8k

Countries citing papers authored by D. Mark Layton

Since Specialization
Citations

This map shows the geographic impact of D. Mark Layton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Mark Layton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Mark Layton more than expected).

Fields of papers citing papers by D. Mark Layton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Mark Layton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Mark Layton. The network helps show where D. Mark Layton may publish in the future.

Co-authorship network of co-authors of D. Mark Layton

This figure shows the co-authorship network connecting the top 25 collaborators of D. Mark Layton. A scholar is included among the top collaborators of D. Mark Layton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Mark Layton. D. Mark Layton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Geraldine, Julian Redhead, Carolyn M. Millar, et al.. (2022). Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation. Blood Advances. 6(13). 3956–3969. 10 indexed citations
2.
Durand‐Zaleski, Isabelle, Paul Baas, David Chao, et al.. (2017). I-O Optimise: Developing A Unique Multinational Real-World Evidence-Based Research Platform In Oncology. Value in Health. 20(9). A742–A743. 1 indexed citations
3.
Caputo, Valentina S., Joana R. Costa, Elisavet Georgiou, et al.. (2013). Mechanism of Polycomb recruitment to CpG islands revealed by inherited disease-associated mutation. Human Molecular Genetics. 22(16). 3187–3194. 6 indexed citations
4.
Almeida, António, Yoshiko Murakami, Alastair Baker, et al.. (2007). Targeted Therapy for Inherited GPI Deficiency. New England Journal of Medicine. 356(16). 1641–1647. 64 indexed citations
5.
Smith, Thomas G., George M. Balanos, D. Mark Layton, et al.. (2007). Mutation of the von Hippel-Lindau Gene Alters Human Cardiopulmonary Physiology. Advances in experimental medicine and biology. 605. 51–56. 14 indexed citations
6.
Almeida, António, Yoshiko Murakami, D. Mark Layton, et al.. (2006). Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nature Medicine. 12(7). 846–851. 156 indexed citations
7.
Bruce, Lesley J., Hélène Guizouarn, Franck Borgèse, et al.. (2005). Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1. Nature Genetics. 37(11). 1258–1263. 114 indexed citations
8.
9.
Vulliamy, Tom, David Roper, Barbara Wild, et al.. (2003). Combined glucose-6-phosphate dehydrogenase and glucosephosphate isomerase deficiency can alter clinical outcome. Blood Cells Molecules and Diseases. 30(3). 258–263. 8 indexed citations
10.
Ofori‐Acquah, Solomon F., M. R. A. LALLOZ, & D. Mark Layton. (2001). Nucleotide Variation Regulates the Level of Enhancement by Hypersensitive Site 2 of the β-Globin Locus Control Region. Blood Cells Molecules and Diseases. 27(5). 803–811. 9 indexed citations
11.
Ohadi, Mina, M. R. A. LALLOZ, Pak C. Sham, et al.. (1999). Localization of a Gene for Familial Hemophagocytic Lymphohistiocytosis at Chromosome 9q21.3-22 by Homozygosity Mapping. The American Journal of Human Genetics. 64(1). 165–171. 138 indexed citations
12.
Humphries, Ann, et al.. (1999). The Consequence of Nucleotide Substitutions in the Triosephosphate Isomerase (TPI) Gene Promoter. Blood Cells Molecules and Diseases. 25(4). 210–217. 5 indexed citations
13.
Humphries, Ann, et al.. (1999). Ancestral origin of variation in the triosephosphate isomerase gene promoter. Human Genetics. 104(6). 486–486. 5 indexed citations
14.
Datz, Christian, M. R. A. LALLOZ, W. Vogel, et al.. (1997). Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. Journal of Hepatology. 27(5). 773–779. 71 indexed citations
15.
Abbas, A., B. Thilaganathan, Andrea G.S. Buggins, D. Mark Layton, & K. H. Nicolaides. (1993). Fetal plasma interferon gamma concentration in normal pregnancy. American Journal of Obstetrics and Gynecology. 168(5). 1414–1416. 7 indexed citations
16.
Walker, Jay, D. Mark Layton, A. J. Bellingham, Michael J. Morgan, & Pelin Faik. (1993). DNA sequence abnormalities in human glucose 6-phosphate isomerase deficiency. Human Molecular Genetics. 2(3). 327–329. 25 indexed citations
17.
Abbas, A., R. J. M. Snijders, Andrea G.S. Buggins, D. Mark Layton, & K. H. Nicolaides. (1993). Fetal Plasma Tumor Necrosis Factor Concentration in Normal Pregnancy. Fetal Diagnosis and Therapy. 8(4). 230–233. 3 indexed citations
18.
Pagliuca, Antonio, et al.. (1989). Myelofibrosis in primary myelodysplastic syndromes: a clinico‐morphological study of 10 cases. British Journal of Haematology. 71(4). 499–504. 77 indexed citations
19.
Layton, D. Mark, et al.. (1988). Sweet's syndrome and myelodysplasia. Annals of Hematology. 56(1). 47–48. 11 indexed citations
20.
Layton, D. Mark & G J Mufti. (1986). Myelodysplastic syndromes: Their history, evolution and relation to acute myeloid leukaemia. Annals of Hematology. 53(6). 423–436. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arnulf Pekrun Breakdown of academic impact, for papers by Jean‐Antoine Ribeil Breakdown of academic impact, for papers by Luciano Baronciani Breakdown of academic impact, for papers by MH Freedman Breakdown of academic impact, for papers by Masue Imaizumi Breakdown of academic impact, for papers by Corinne Pondarré Breakdown of academic impact, for papers by Alessandra Meloni Breakdown of academic impact, for papers by Fiorina Giona Breakdown of academic impact, for papers by Tohru Ikuta Breakdown of academic impact, for papers by William Krivit
Rankless by CCL
2026